XELIS FUSION
K111613 · Infinitt Co., Ltd. · LLZ · Sep 8, 2011 · Radiology
Device Facts
| Record ID | K111613 |
| Device Name | XELIS FUSION |
| Applicant | Infinitt Co., Ltd. |
| Product Code | LLZ · Radiology |
| Decision Date | Sep 8, 2011 |
| Decision | SESE |
| Submission Type | Traditional |
| Regulation | 21 CFR 892.2050 |
| Device Class | Class 2 |
| Attributes | Software as a Medical Device |
Intended Use
The Xelis Fusion™ is a software device that receives digital images and data from various sources (e.g. CT scanners, MR scanners, ultrasound systems, R/F Units, computed & direct radiographic devices, secondary capture devices, scanners, imaging gateways or other imaging sources). Diagnosis or computer aided diagnosis is not performed by the software but by Radiologists. Images (including mammographic) and data can be stored, communicated, processed and displayed within the system and or across computer networks at distributed locations. In addition, Xelis Fusion™ can be integrated with an institutions HIS or RIS for an integrated an electronic patient record. Lossy compressed mammographic images and digitized film screen images must not be reviewed for primary image interpretation. Mammographic images may only be interpreted using an FDA approved monitor that offers at least 5 Mega-pixel resolution and meets other technical specifications reviewed and accepted by FDA.
Device Story
XELIS Fusion is a PACS software package for viewing/manipulating DICOM-compliant medical images from CT, PET, MRI, and other modalities. It enables real-time viewing, 3D volume rendering, segmentation, registration, and reporting. Used in clinical settings by radiologists and physicians to display and process images across hospital networks; integrates with HIS/RIS for electronic patient records. The device does not perform automated detection or diagnosis; it serves as a visualization tool for human interpretation. By facilitating efficient image access and manipulation, it supports clinical decision-making and diagnostic workflows.
Clinical Evidence
Bench testing only. Validation testing evaluated all input/output functions and operational modes against a System Validation Test Plan. Results confirmed that all predetermined acceptance criteria were met.
Technological Characteristics
PACS software; DICOM 3.0 compliant; supports 3D volume rendering, segmentation, and registration. Operates on Windows 32-bit/64-bit systems. Connectivity via DICOM to workstations, PACS servers, and imaging modalities. No patient-contacting components; does not control life-sustaining equipment.
Indications for Use
Indicated for use by radiologists and clinicians to receive, store, communicate, process, and display digital medical images (CT, MR, ultrasound, R/F, radiographic) for diagnostic review. Not for automated diagnosis. Mammographic images require 5MP FDA-approved monitors; lossy compressed mammographic/digitized film images prohibited for primary interpretation.
Regulatory Classification
Identification
A medical image management and processing system is a device that provides one or more capabilities relating to the review and digital processing of medical images for the purposes of interpretation by a trained practitioner of disease detection, diagnosis, or patient management. The software components may provide advanced or complex image processing functions for image manipulation, enhancement, or quantification that are intended for use in the interpretation and analysis of medical images. Advanced image manipulation functions may include image segmentation, multimodality image registration, or 3D visualization. Complex quantitative functions may include semi-automated measurements or time-series measurements.
Special Controls
*Classification.* Class II (special controls; voluntary standards—Digital Imaging and Communications in Medicine (DICOM) Std., Joint Photographic Experts Group (JPEG) Std., Society of Motion Picture and Television Engineers (SMPTE) Test Pattern).
Predicate Devices
- INFINITT XELIS (K082990)
- Voxar 3D Enterprise with ColonMetrix and PET/CT Perfusion (K070831)
Related Devices
- K103130 — XELIS 3D · Infinitt Co., Ltd. · Jul 28, 2011
- K173475 — Merge PACS · Merge Healthcare Incorporated · Dec 8, 2017
- K020995 — EFILM WORKSTATION WITH MODULES · Efilm Medical, Inc. · Apr 12, 2002
- K192508 — Medsynapse Ris Pacs & Medsynapse VNA · Medsynaptic Private, Ltd. · Nov 22, 2019
- K192455 — Merge PACS · Merge Healthcare Incorporated · Oct 17, 2019
Submission Summary (Full Text)
{0}------------------------------------------------
510(k) Summary of Safety
K111613
This 510(k) summary of safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990.
Date Prepared: May 28, 2011
SEP - 8 2011
Submitter's Information: 21 CFR 807.92(a)(1) Mr. Tristan Choi, Program Manager INFINITT Co., Ltd. 12F Daerung Post Tower III, 182-4 Guro-dong, Guro-gu, Seoul, 152-050. Korea Tel: +82-2-2194-6673 Fax: +82-2-2194-1698
Trade Name, Common Name and Classification: 21 CFR 807.92(a)(2)
| Trade Name: | XELIS Fusion |
|------------------------|-----------------------------------------|
| Common Name: | Picture Archiving Communications System |
| Classification Name: | system, image processing, radiological |
| Product code: | LLZ |
| Device Classification: | 892.2050 |
Predicate Device: 21 CFR 807. 92(a)(3)
| 510(k) Number | K082990 | K070831 |
|--------------------------------------|-------------------------------------------|-----------------------------------------------------------------|
| Device Classification<br>Name | System, image<br>processing, radiological | System, image<br>processing, radiological |
| Device Name | INFINITT XELIS | Voxar 3D Enterprise with<br>ColonMetrix and PET/CT<br>Perfusion |
| Applicant | INFINITT CO., LTD | BARCOVIEW MIS<br>EDINBURGH |
| Regulation Number | 892.2050 | 892.2050 |
| Classification Product<br>Code | LLZ | LLZ |
| Decision Date | 11/20/2008 | 05/22/2007 |
| Classification Advisory<br>Committee | Radiology | Radiology |
| Type | Traditional | Traditional |
Device Description: 21 CFR 807 92(a)(4)
XELIS Fusion is a Picture Archive and Communications System (PACS) software package intended for viewing and manipulating DICOM-compliant medical images from CT (computerized tomography), PET (positron emission tomography) or MRI (magnetic resonance imaging) scanners and other imaging modalities. XELIS Fusion can be used for real-time viewing, 3D volume rendering, segmentation, registration, and reporting. XELIS Fusion application conforms to the DICOM 3.0 standard to allow interoperability with other DICOM compliant systems and is based upon the predicate device software used in Infinitt Xelis K082990. XELIS Fusion does not include any automated or semiautomated process for the detection of nodules or other shapes.
{1}------------------------------------------------
### 510(k) Summary of Safety
XELIS 3D Fusion is supplied to end users in both Windows 32 bit and 64 bit operating systems. The device software can connect to other workstations, PACS server/software, and modalities, through DICOM communication standard.
#### Indications for Use: 21 CFR 807 92(a)(5)
The Xelis Fusion™ is a software device that receives digital images and data from various sources (e.g. CT scanners, MR scanners, ultrasound systems, R/F Units, computed & direct radiographic devices, secondary capture devices, scanners, imaging gateways or other imaging sources). Diagnosis or computer aided diagnosis is not performed by the software but by Radiologists.
Images (including mammographic) and data can be stored, communicated, processed and displayed within the system and or across computer networks at distributed tocations. In addition, Xelis Fusion™ can be integrated with an institutions HIS or RIS for an integrated an electronic patient record.
Lossy compressed mammographic images and digitized film screen images must not be reviewed for primary image interpretation. Mammographic images may only be interpreted using an FDA approved monitor that offers at least 5 Mega-pixel resolution and meets other technical specifications reviewed and accepted by FDA.
#### Technological Characteristics: 21 CFR 807 92(a)(6)
XELIS Fusion is a PACS software device that does not contact the patient, nor does it control any life sustaining devices. Diagnosis is not performed by the software but by Radiologists, Clinicians and referring Physicians.
Diagnosis or computer aided diagnosis is not performed by the software but by Radiologists. A physician, providing ample opportunity for competent human intervention interprets images and information being displayed and printed.
The new device and predicate devices are substantially equivalent in the areas of technical characteristics, general function, application, and intended use. The new device does not raise any new potential safety risks and is equivalent in performance to the existing legally marketed devices.
#### Nonclinical Testing:
The complete system configuration has been assessed and tested at the factory and has passed all in-house testing criteria. The Validation Test Plan was designed to evaluate all input functions, output functions, and actions performed by the XELIS Fusion software in each operational mode and followed the process documented in the System Validation Test Plan.
Nonclinical testing results are provided in the 510(k). Validation testing indicated that as required by the risk analysis, designated individuals performed all verification and validation activities and that the results demonstrated that the predetermined acceptance criteria were met.
If the device is installed by INFINITT CO., LTD, integration and installations verification tests are conducted against acceptance criteria prior to release to the client. results are provided in the 510(k)
#### Conclusion: 21 CFR 807 92(b)(1)
The 510(k) Pre-Market Notification for XELIS Fusion contains adequate information, data, and nonclinical test results to enable FDA - CDRH to determine substantial equivalence to the predicate device.
{2}------------------------------------------------
## 510(k) Summary of Safety
The subject device will be manufactured in accordance with the voluntary standards listed in the enclosed voluntary standard survey. The new device and predicate devices are substantially equivalent in the areas of technical characteristics, general function. application, and intended use does not raise any new potential safety risks and is equivalent in performance to existing legally marketed devices.
Nonclinical tests demonstrate that the device is as safe, as effective, and performs as well as the predicate devices.
Therefore, XELIS Fusion is substantially equivalent to the predicate devices.
{3}------------------------------------------------
Image /page/3/Picture/0 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo consists of a stylized eagle with three stripes forming its body and wing. The eagle is facing right. Encircling the eagle is the text "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" in a circular arrangement.
## DEPARTMENT OF HEALTH & HUMAN SERVICES
Public Health Service
Food and Drug Administration 10903 New Hampshire Avenue Document Control Room - WO66-G609 Silver Spring, MD 20993-0002
INFINITT Co.. Ltd. % Mr. Carl Alletto Consultant OTech, Inc. 1600 Manchester Way CORINTH TX 76210
SEP - 8 2011
Rc: K111613
Trade/Device Name: Xelis Fusion Regulation Number: 21 CFR 892.2050 Regulation Name: Picture archiving and communications system Regulatory Class: II Product Code: LLZ Dated: June 1, 2011 Received: June 15, 2011
Dear Mr. Alletto:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into class II (Special Controls), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reportion of
{4}------------------------------------------------
medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 1 809), please contact the Office of In Viro Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportalProblem/default.htm for the CDRH's Office
of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely Yours,
Mary Patel
Mary S. Pastel, Sc.D. Director Division of Radiological Devices Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health
Enclosure
{5}------------------------------------------------
# Indications for Use
KIII 613
510(k) Number (if known):
Device Name: Xelis Fusion
Indications for Use:
The Xelis Fusion™ is a software device that receives digital images and data from various sources (e.g. CT scanners, MR scanners, ultrasound systems, R/F Units, computed & direct radiographic devices, secondary capture devices, scanners, imaging gateways or other imaging sources). Diagnosis or computer aided diagnosis is not performed by the software but by Radiologists.
Images (including mammographic) and data can be stored, communicated, processed and displayed within the system and or across computer networks at distributed locations. In addition, Xelis Fusion™ can be integrated with an institutions HIS or RIS for an integrated an electronic patient record.
Lossy compressed mammographic images and digitized film screen images must not be reviewed for primary image interpretation. Mammographic images may only be interpreted using an FDA approved monitor that offers at least 5 Mega-pixel resolution and meets other technical specifications reviewed and accepted by FDA.
Prescription Use X (Part 21 CFR 801 Subpart D) AND/OR
Over-The-Counter Use (21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)
Mary S Roth
(Division Sign-Off) Division of Radiological Devices Office of In Vitro Diagnostic Device Evaluation and Safety
510(k) Number
Page I of